论文部分内容阅读
目的评价甘精胰岛素(商品名长秀霖)联合格列吡嗪控释片(瑞易宁)治疗口服降糖药血糖控制不佳的2型糖尿病的有效性和安全性。方法共选择40例2型糖尿病患者随机分为2组,对照组10例,给予诺和灵N皮下注射与瑞易宁口服;试验组30例,给予甘精胰岛素皮下注射与瑞易宁口服,疗程12周。结果12周后,40例患者HbAlc和空腹血糖达标水平分别为<7．5％和≤6．7 mmol／L, 2组间HbAlc、空腹血糖和HbAlc+空腹血糖的达标率无差异(P>0．05),低血糖和夜间低血糖的受试者例数相当,无严重低血糖事件,BMI平均增加0．43和0．66,两组间无差异(P>0．05),两组治疗前后收缩压、舒张压及静息心率无明显改变。结论甘精胰岛素和诺和灵N分别与格列吡嗪控释片联合应用疗效相当,且具有良好的耐受性。
Objective To evaluate the efficacy and safety of insulin glargine (Chang-Lin-Lin) and glipizide-controlled release tablets (Rui Yi Ning) in the treatment of type 2 diabetes with poorly controlled oral glucose-lowering drugs. Methods A total of 40 patients with type 2 diabetes mellitus were randomly divided into two groups, the control group of 10 cases, noradrenaline N subcutaneous injection with Rui Yi Ning oral; experimental group of 30 patients given insulin glargine subcutaneously and Rui Yi Ning oral, Treatment for 12 weeks. Results After 12 weeks, the compliance rates of HbA1c and fasting blood glucose in the 40 patients were <7.5% and ≤ 6.7 mmol / L, respectively. There was no difference in the compliance rates of HbA1c, fasting plasma glucose and HbA1c + fasting plasma glucose between the two groups .05). The number of subjects with hypoglycemia and nocturnal hypoglycemia was comparable, without severe hypoglycemia, the mean BMI increased by 0.43 and 0.66, respectively, with no significant difference between the two groups (P> 0.05) Before and after treatment systolic blood pressure, diastolic blood pressure and resting heart rate did not change significantly. Conclusion Glargine and noradrenonol, respectively, with glipizide controlled release tablets in combination with similar efficacy, and has good tolerance.